""Pancreatic cancer remains one of the most challenging solid tumors to treat, but these findings provide cautious optimism for patients.""
""While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging.""
""Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumor types.""
A phase 2 clinical trial demonstrated that elraglusib, an experimental drug, combined with standard chemotherapy, significantly improves survival rates for pancreatic cancer patients. Patients receiving the drug were twice as likely to survive one year compared to those on chemotherapy alone. The trial involved 233 patients across 60 sites in North America and Europe. This study represents one of the few successful trials in the past decade, indicating potential for broader applications in treating other tumor types.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]